Assembly Biosciences has evolved into a strategically financed antiviral platform, underpinned by a

Mizuho analyst Salim Syed maintains Assembly Biosciences (NASDAQ:ASMB) with a Outperform and rais

Assembly Biosciences NASDAQ: ASMB outlined its antiviral and liver disease development strategy duri

Assembly Biosciences, Inc. (ASMB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference

Assembly Biosciences NASDAQ: ASMB is awaiting a key development plan from partner Gilead Sciences fo

SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: AS

Guggenheim analyst Vamil Divan reiterates Assembly Biosciences (NASDAQ:ASMB) with a Buy and maint

SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: AS

US stocks rose, Dow gained over 400 points. S&P 500 and NASDAQ also up. Health care shares jumpe

Zoom Communications Inc shares rise after strong financial results and increased buyback authorizat

Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics

"We are excited to expand the ABI-6250 program into PBC and PSC, where there remains significant

SOUTH SAN FRANCISCO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: AS

– Phase 2 study in cholestatic liver diseases, focused on PBC and PSC, anticipated to initiate in Q1

Assembly Biosciences NASDAQ: ASMB Chief Medical Officer Anuj Gaggar outlined the company's virology

Assembly Biosciences, Inc. (ASMB) Presents at Bank of America Global Healthcare Conference 2026 Tran

SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: AS

SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: AS

Assembly Biosciences (ASMB) came out with a quarterly loss of $0.54 per share versus the Zacks Conse

Assembly Biosciences (NASDAQ:ASMB) reported quarterly losses of $(0.54) per share which beat the ana

– Completed Phase 1b studies for ABI-5366 and ABI-1179, helicase-primase inhibitors for recurrent ge

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Assembly Biosciences (NASDAQ:ASMB)

– Additional Phase 1b data for ABI-5366, including results from monthly dosing cohort, selected for

– Additional Phase 1b data for ABI-5366, including results from monthly dosing cohort, selected for

Guggenheim analyst Vamil Divan maintains Assembly Biosciences (NASDAQ:ASMB) with a Buy and raises

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Assembly Biosciences (NASDAQ:ASMB)

Assembly Biosciences, Inc. (NASDAQ: ASMB - Get Free Report) has been given a consensus rating of "Mo

Assembly Biosciences, Inc. remains a Buy as Gilead licensed its HPI program, triggering a $35M payme

Scholastic Corp (NASDAQ: SCHL) rose 10.7% on Friday after reporting better-than-expected earnings an

Assembly Biosciences (ASMB) came out with quarterly earnings of $2.48 per share, beating the Zacks C

Assembly Biosciences (NASDAQ:ASMB) reported quarterly earnings of $1.30 per share which beat the ana

– Successfully licensed helicase-primase inhibitor program for recurrent genital herpes to Gilead, i

Assembly Biosciences, Inc. (NASDAQ: ASMB - Get Free Report)'s stock price passed above its 200-day m

Gilead licensed Assembly Bio's long-acting HSV drugs after Phase 1b data showed antiviral activi

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Assembly Biosciences (NASDAQ:ASMB)

Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (NASDAQ:ASMB), today announced G

Mizuho analyst Salim Syed maintains Assembly Biosciences (NASDAQ:ASMB) with a Outperform and rais

Assembly Biosciences (NASDAQ:ASMB) reported quarterly losses of $(0.72) per share which beat the ana

Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutic

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Assembly Biosciences (NASDAQ:ASMB)

Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrati

JMP Securities analyst Roy Buchanan initiates coverage on Assembly Biosciences (NASDAQ:ASMB) with

Guggenheim analyst Vamil Divan maintains Assembly Biosciences (NASDAQ:ASMB) with a Buy and raises

  Monday saw 196 companies set new 52-week lows.

  On Wednesday, 807 companies reached new 52-week lows.

    On Wednesday, 348 companies hit new 52-week lows.

    During Tuesday's trading, 505 companies set new 52-week lows.

    On Friday, 313 companies hit new 52-week lows.